bs-6136R [Primary Antibody]
Adenovirus 5 E1A Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: Adenovirus 5 E1A

Immunogen Range: 181-280/289


Clonality: Polyclonal

Isotype: IgG

Swiss Prot: P03255

Source: KLH conjugated synthetic peptide derived from human Adenovirus 5 E1A

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

The early region (E1) of the adenovirus genome, responsible for transforming activity, is localized within the left most 11% of the viral genome and consists of two transcriptional units E1A and E1B. E1A is sufficient for partial transformation and immortalization of primary cells. E1A gene products are necessary for normal levels of transcription of the other early regions of the adenovirus genome during productive infection and are able to either activate or repress the transcription of specific cellular genes. E1A forms specific complexes with cellular proteins including p105 causing inhibition of the cell cycle inducing arresting function of p105.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 32


Cross Reactive Species: Rat
Virus
(Adenovirus5)

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: rat brain lysates Lane 2: rat liver lysates probed with Anti Adenovirus 5 E1A Polyclonal Antibody, Unconjugated (bs-6136R) at 1:200 in 4˚C. Followed by conjugation to secondary antibody (bs-0295G-HRP) at 1:3000 90min in RT. Predicted band 32kD. Observed band size: 32kD


Lane 1: Recombinant ADV 5E1A protein, His probed with Adenovirus 5 E1A Polyclonal Antibody, Unconjugated (bs-6136R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.